Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
__cf_bm
1 hour
This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
_cfuvid
session
Calendly sets this cookie to track users across sessions to optimize user experience by maintaining session consistency and providing personalized services
cookielawinfo-checkbox-analytics
1 year
Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Analytics" category.
cookielawinfo-checkbox-functional
1 year
The GDPR Cookie Consent plugin sets the cookie to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
1 year
Set by the GDPR Cookie Consent plugin, this cookie records the user consent for the cookies in the "Necessary" category.
CookieLawInfoConsent
1 year
CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
rc::a
never
This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
rc::c
session
This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
viewed_cookie_policy
1 year
The GDPR Cookie Consent plugin sets the cookie to store whether or not the user has consented to use cookies. It does not store any personal data.
wpEmojiSettingsSupports
session
WordPress sets this cookie when a user interacts with emojis on a WordPress site. It helps determine if the user's browser can display emojis properly.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Cookie
Duration
Description
_ga
1 year 1 month 4 days
Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*
1 year 1 month 4 days
Google Analytics sets this cookie to store and count page views.
